FDA com­mis­sion­er Scott Got­tlieb just broke a pub­lic promise on pub­lish­ing CRLs — and yes, it mat­ters

8 years ago
Bioregnum
Pharma

AveX­is wants $400M more for promis­ing SMA gene ther­a­py; Shang­Phar­ma part­ners with Ic­ahn School of Med­i­cine at Mount ...

8 years ago
News Briefing

Chi­na biotech uni­corn In­novent in talks on $200M IPO and new fund­ing — re­port

8 years ago
Financing

De­vel­op­ers are lay­ing the foun­da­tion for a new biotech com­plex in Cal­i­for­nia

8 years ago
Pharma

Ger­man drug­mak­er files $21.6M IPO for skin can­cer drug

8 years ago
Financing

Eiger Bio scraps a mid-stage pro­gram af­ter re­searchers record a clear flop in PAH, shares skid low­er

8 years ago
R&D

Mer­ck’s Keytru­da com­bo wows again, ac­ing PhI­II over­all sur­vival goal for lung can­cer ear­ly

8 years ago
R&D

Pre­clin­i­cal study finds Gen­mab may hold the key to a next-gen triple fol­lowup to MEK/BRAF com­bos

8 years ago
Discovery

Google backs $27M launch round for Holy Grail R&D work on two tar­gets: a can­cer vac­cine and a uni­ver­sal flu jab

8 years ago
Financing
Startups

Scoop: With its NDA in lim­bo, Iron­shore ex­ecs shut­tered the AD­HD biotech

8 years ago
Pharma

Video: How many PD-1/L1 drugs do we need? Where is im­munother­a­py head­ed? Watch Jay Brad­ner, Hervé Hop­penot, Ellen ...

8 years ago
Special
Pharma

HHS pick Azar draws the line on drug price ne­go­ti­a­tions at Medicare; As­traZeneca inks on­col­o­gy re­search deal at JPM

8 years ago
News Briefing

In a pi­o­neer­ing first, As­traZeneca scores FDA OK to use its PARP against breast can­cer

8 years ago
Pharma

The Cam­bridge siren call: Philips NV mov­ing HQ to mega-project Cam­bridge Cross­ing

8 years ago
Pharma

Why did Abl­ynx board chair­man Pe­ter Fell­ner re­sign in wake of Novo's buy­out of­fer?; Am­gen vet Richard Paul­son tapped ...

8 years ago
Peer Review

Jump­ing on an­ti-ag­ing band­wag­on, Y Com­bi­na­tor joins hunt for the $100B pill

8 years ago
Startups

Head­ed for a block­buster smash, Roche picks up an­oth­er key OK for land­mark MS drug Ocre­vus

8 years ago
Pharma

Genen­tech beefs up its PD-L1 com­bo pipeline, sign­ing the 'don’t eat me' spe­cial­ists at Forty Sev­en

8 years ago
Pharma

Brae­burn bags $110M in launch cash as PDU­FA date rolls up; En­do sub­poe­naed for doc­u­ments on opi­oid painkillers

8 years ago
News Briefing

New study looks at FDA's use of so­cial me­dia to com­mu­ni­cate on drug safe­ty

8 years ago
Pharma

Teva's board slash­es its own com­pen­sa­tion fol­low­ing mas­sive re­struc­tur­ing

8 years ago
R&D

Shire CEO Flem­ming Orn­skov is hatch­ing a few new stretch goals for R&D in 2018 — and be­yond

8 years ago
People

Charles Riv­er buys KWS BioTest for $20M, gain­ing im­munol­o­gy dis­cov­ery ca­pac­i­ty and a UK foot­print

8 years ago
Deals
Outsourcing

Pfiz­er on­col­o­gy head Liz Bar­rett jumps ship to No­var­tis as Bruno St­rig­i­ni steps aside

8 years ago
People
First page Previous page 1068106910701071107210731074 Next page Last page
A service from the Financial Times